Cardiff Oncology Management
Management criteria checks 3/4
Cardiff Oncology's CEO is Mark Erlander, appointed in May 2020, has a tenure of 3.92 years. total yearly compensation is $3.18M, comprised of 17.9% salary and 82.1% bonuses, including company stock and options. directly owns 0.055% of the company’s shares, worth $106.75K. The average tenure of the management team and the board of directors is 2.3 years and 9.6 years respectively.
Key information
Mark Erlander
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 17.9% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2.3yrs |
| Board average tenure | 9.6yrs |
Recent management updates
Recent updates
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year
Dec 02
Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market
Nov 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$39m |
| Dec 31 2022 | US$3m | US$571k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$4m | US$533k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$1m | US$445k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$853k | US$399k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$909k | US$387k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$20m |
| Dec 31 2017 | US$1m | US$374k | -US$25m |
Compensation vs Market: Mark's total compensation ($USD3.18M) is above average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Erlander (63 yo)
3.9yrs
Tenure
US$3,180,694
Compensation
Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.9yrs | US$3.18m | 0.055% $ 106.7k | |
| Chief Financial Officer | 2.8yrs | US$1.92m | 0.13% $ 261.6k | |
| Chief Scientific Officer? | 2.3yrs | US$4.17m | 0% $ 0 | |
| VP of Finance & Administration | 8.8yrs | no data | no data | |
| Senior Vice President of Finance | 1.3yrs | no data | no data | |
| Senior VP of Regulatory Affairs | 2.3yrs | no data | no data | |
| Chief Medical Officer | 1.2yrs | no data | no data |
2.3yrs
Average Tenure
60.5yo
Average Age
Experienced Management: CRDF's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$3.18m | 0.055% $ 106.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4yrs | US$132.73k | 1.56% $ 3.0m | |
| Member of Scientific Advisory Board | 9.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 11.4yrs | US$35.85k | no data | |
| Independent Chairman of the Board | 10.2yrs | US$172.73k | 0.070% $ 135.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 14yrs | no data | no data | |
| Independent Director | 4yrs | US$132.73k | 0.27% $ 533.4k | |
| Member of Scientific Advisory Board | 9.6yrs | no data | no data | |
| Independent Director | 2.8yrs | US$128.73k | 0.022% $ 43.6k | |
| Member of Scientific Advisory Board | 14yrs | no data | no data |
9.6yrs
Average Tenure
71yo
Average Age
Experienced Board: CRDF's board of directors are considered experienced (9.6 years average tenure).